Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy

Journal of Clinical Investigation

Volumn 114, Issue 10, 2004, Pages 1504-1511

  Hunter, R Bridge ^a   Kandarian, Susan C ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; MUSCLE PROTEIN; MYOSIN; PROTEIN BCL 3; PROTEIN P105; PROTEIN P50; NFKB1 PROTEIN, MOUSE; ONCOPROTEIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCL3 GENE; CONTROLLED STUDY; FAST MUSCLE FIBER; FEMALE; FUNCTIONAL DISEASE; GENE; GENE ACTIVATION; GENE DISRUPTION; GENE FUNCTION; GENE INDUCTION; IMMOBILIZATION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; MOUSE STRAIN; MUSCLE ATROPHY; NFKB1 GENE; NONHUMAN; PARAMETER; PHENOTYPE; PLANTARIS MUSCLE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SLOW MUSCLE FIBER; SOLEUS MUSCLE; WILD TYPE; ANIMAL; COMPARATIVE STUDY; GENETICS; METABOLISM; MOUSE MUTANT; NASA DISCIPLINE MUSCULOSKELETAL; NON-NASA CENTER; TIME;

NASA DISCIPLINE MUSCULOSKELETAL; NON-NASA CENTER;

ANIMALS; FEMALE; GENES, REPORTER; HINDLIMB SUSPENSION; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MUSCLE FIBERS, FAST-TWITCH; MUSCLE FIBERS, SLOW-TWITCH; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PROTO-ONCOGENE PROTEINS; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 11144317940     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200421696     Document Type: Article

References (57)

1. Booth, F., and Baldwin, K. 1996. Muscle plasticity: energy demand/supply processes. In Exercise: regulation and integration of multiple systems. L. Rowell and J. Sheperd, editors. Published for the American Physiological Society. Oxford University Press. New York, New York, USA. 1075-1123.
2. Thomason, D.B., and Booth, F.W. 1990. Atrophy of the soleus muscle by hindlimb umweighting. J. Appl. Physiol. 68:1-12.
3. Zimmers, T.A., et al. 2002. Induction of cachexia in mice by systemically administered myostatin. Science. 296:1486-1488.
4. Sharma, M., Langley, B., Bass, J., and Kambadur, R. 2001. Myostatin in muscle growth and repair. Exerc. Sport Sci. Rev. 29:155-158.
5. Tischler, M.E. 1994. Effect of the antiglucocorticoid RU38486 on protein metabolism in unweighted soleus muscle. Metabolism. 43:1451-1455.
6. McMahon, C.D., et al. 2003. Myostatin-deficient mice lose more skeletal muscle mass than wild-type controls during hindlimb suspension. Am. J. Physiol. Endocrinol Metab. 285:E82-E87.
7. Bodine, S.C., et al. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3:1014-1019.
8. Reynolds, T.H., 4th, Bodine, S.C., and Lawrence, J.C., Jr. 2002. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J. Biol. Chem. 277:17657-17662.
9. Hornberger, T.A., Hunter, R.B., Kandarian, S.C., and Esser, K.A. 2001. Regulation of translation factors during hindlimb unloading and denervation of skeletal muscle in rats. Am. J. Physiol. Cell Physiol. 281:C179-C187.
10. Hunter, R.B., et al. 2002. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J. 16:529-538.
11. Mitch, W.E., and Price, S.R. 2001. Transcription factors and muscle cachexia: is there a therapeutic target? Lancet. 357:734-735.
12. Hasselgren, P.O., and Fischer, J.E. 2001. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann. Surg. 233:9-17.
13. Guttridge, D.C., Mayo, M.W., Madrid, L.V., Wang, C.Y., and Baldwin, A.S., Jr. 2000. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 289:2363-2366.
14. Li, Y.P., and Reid, M.B. 2000. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279:R1165-R1170.
15. Senftleben, U, and Karin, M. 2002. The IKK/NF-kappaB pathway. Crit. Care Med. 30(Suppl. 1):S18-S26.
16. Ghosh, S., May, M.J., and Kopp, E.B. 1998. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225-260.
17. Yamamoto, Y., and Gaynor, R.B. 2004. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci. 29:72-79.
18. Thornburg, N.J., Pathmanathan, R., and Raab-Traub, N. 2003. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 63:8293-8301.
19. Caamano, J.H., Perez, P., Lira, S.A., and Bravo, R. 1996. Constitutive expression of Bcl-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol. Cell. Biol. 16:1342-1348.
20. Watanabe, N., Iwamura, T., Shinoda, T., and Fujita, T. 1997. Regulation of NFkB1 proteins by the candidate oncoprotein Bcl-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. EMBO J. 16:3609-3620.
21. Dechend, R., et al. 1999. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene. 18:3316-3323.
22. Franzoso, G., et al. 1992. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappaB-mediated inhibition. Nature. 359:339-342.
23. Bours, V., et al. 1993. The oncoprotein Bcl-3 directly transactivates through kappaB motifs via association with DNA-binding p50B homodimers. Cell. 72:729-739.
24. Fujita, T., Nolan, G.P., Liou, H.C., Scott, M.L., and Baltimore, D. 1993. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 7:1354-1363.
25. Vandenburgh, H., et al. 1998. Attenuation of skeletal muscle wasting with recombinant human growth hormone secreted from a tissue-engineered bioartificial muscle. Hum. Gene Ther. 9:2555-2564.
26. Kasper, C.E., and Xun, L. 1996. Cytoplasm-to-myonucleus ratios in plantaris and soleus muscle fibres following hindlimb suspension. J. Muscle Res. Cell Motil. 17:603-610.
27. Mitchell, P.O., and Pavlath, G.K. 2001. A muscle precursor cell-dependent pathway contributes to muscle growth after atrophy. Am. J. Physiol. Cell Physiol. 281:C1706-C1715.
28. Saltin, B., and Gollnick, P.D. 1983. Skeletal muscle adaptability: significance for metabolism and performance. In Skeletal muscle. R. H. Adrian, editor. American Physiological Society. Bethesda, Maryland, USA. 555-631.
29. Tidball, J.G., and Spencer, M.J. 2002. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J. Physiol. 545:819-828.
30. Pette, D., and Staron, R.S. 2001. Transitions of muscle fiber phenotyptc profiles. Histochem. Cell Biol. 115:359-372.
31. Templeton, G.H., Sweeney, H.L., Timson, B.F., Padalino, M., and Dudenhoeffer, G.A. 1988. Changes in fiber composition of soleus muscle during rat hindlimb suspension J. Appl. Physiol. 65:1191-1195.
32. Heissmeyer, V., Krappmann, D., Wulczyn, F.G., and Scheidereit, C. 1999. NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J. 18:4766-4778.
33. Li, Y.P., et al. 2003. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J. 17:1048-1057.
34. Stevenson, E.J., Giresi, P.G., Koncarevic, A., and Kandarian, S.C. 2003. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J. Physiol. 551:33-48.
35. Sandri, M., et al. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399-412.
36. Lecker, S.H. 2003. Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways? Curr. Opin. Clin. Nutr. Metab. Care. 6:271-275.
37. Hershko, A., and Ciechanover, A. 1998. The ubiquitin system. Annu. Ref. Biochem. 67:425-479.
38. Bodine, S.C., et al. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:1704-1708.
39. Gomes, M.D., Lecker, S.H. Jagoe, R.T., Navon, A., and Goldberg, A.L. 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad Sci. U. S. A. 98:14440-14445.
40. Pallafacchina, G., Calabria, E., Serrano, A.L., Kalhovde, J.M., and Schiaffino, S. 2002. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. U. S. A. 99:9213-9218.
41. Rommel, C., et al. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by P1(3)K/ Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:1009-1013.
42. Sun, T.N., et al. 2004. The IGF-1/P13K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14:395-403.
43. Kondo, H., Miura, M., and Itokawa, Y. 1991. Oxidative stress in skeletal muscle atrophied by immobilization. Acta Physiol. Scand. 142:527-528.
44. Lawler, J.M., Song, W., and Demaree, S.R. 2003. Hindlimb unloading increases oxidative stress and disrupts antioxidant capacity in skeletal muscle. Free Radic. Biol. Med. 35:9-16.
45. Gomes-Marcondes, M.C., and Tisdale, M.J. 2002. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 180:69-74.
46. Li, Y.P., Chen, Y., Li, A.S., and Reid, M.B. 2003. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am. J. Physiol. Cell Physiol. 285:C806-C812.
47. Li, Y.P., Schwartz, R.J., Waddell, I.D., Holloway, B.R., and Reid, M.B. 1998. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 12:871-880.
48. Furukawa-Hibi, Y., Yoshida-Araki, K., Ohta, T., Ikeda, K., and Motoyama, N. 2002. FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J. Biol. Chem. 277:26729-26732.
49. Jankala, H., Harjola, V.P., Petersen, N.B., and Harkonen, M. 1997. Myosin heavy chain mRNA transform to faster isoforms in immobilized skeletal muscle: a quantitative PCR study. J. Appl. Physiol. 82:977-982.
50. Dupont-Versteegden, E.E., Knox, M., Gurley, C.M., Houle, J.D., and Peterson, C.A. 2002. Maintenance of muscle mass is not dependent on the calcineurin-NFAT pathway. Am. J. Physiol. Cell Physiol. 282:C1387-C1395.
51. Caiozzo, V.J., Haddad, P., Baker, M.J., and Baldwin, K.M. 1995. Functional and cellular adaptations of rodent skeletal muscle to weightlessness. J. Gravit. Physiol. 2:P39-P42.
52. Widrick, J.J., et al. 1997. Effect of 17 days of bed rest on peak isometric force and unloaded shortening velocity of human soleus fibers. Am. J. Physiol. 273:C1690-C1699.
53. Lin, J., et al. 2002. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 418:797-801.
54. Olson, E.N., and Williams, R.S. 2000. Remodeling muscles with calcineurin. Bioessays. 22:510-519.
55. Peters, D.G., Mitchell-Felton, H., and Kandarian, S.C. 1999. Unloading induces transcriptional activation of the sarco(endo)plasmic reticulum Ca2+-ATPase 1 gene in muscle. Am. J. Physiol. 276:C1218-C1225.
56. Durand, D.B., et al. 1988. Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol. Cell. Biol. 8:1715-1724.
57. Mitchell-Felton, H., and Kandarian, S.C. 1999. Normalization of muscle plasmid uptake by Southern blot: application to SERCA1 promoter analysis. Am. J. Physiol. 277:C1269-C1276.